Swedish CubaseBio Emerges From Stealth with €5.9 Million to Scale Volumetric DNA Microscopy

Why It Matters

Scalable 3‑D spatial transcriptomics can dramatically shorten target validation cycles, giving pharma and biotech a powerful tool for precision medicine research.

Key Takeaways

• €5.9M blended financing secured.
• Combines €2M EIC grant with €3.9M venture funds.
• Enables true 3D gene expression mapping.
• Founded by ex‑CARTANA team, acquired by 10x.
• Targets drug discovery and disease research markets.

Pulse Analysis

Volumetric DNA microscopy addresses a critical gap in spatial biology by capturing transcriptomic data in three dimensions without the need for tissue sectioning. Traditional 2‑D spatial transcriptomics platforms, while valuable, are limited to thin slices that miss cellular context in complex tissues such as organoids or whole embryos. CubaseBio’s approach reconstructs a proximity matrix from DNA sequencing reads, delivering a computationally derived 3‑D image that retains both spatial coordinates and nucleotide‑level information, positioning the company at the forefront of next‑generation spatial omics.

The €5.9 million financing package illustrates growing confidence in European deep‑tech life‑science ventures. The non‑dilutive €2 million grant from the European Innovation Council validates the technology’s scalability and disruptive potential, while the €3.9 million equity infusion from seasoned investors like Voima Ventures and Illumina Ventures provides the commercial muscle needed for rapid market entry. Backed by founders who previously built CARTANA—later integrated into 10x Genomics’ Xenium platform—CubaseBio benefits from proven execution experience and a network that can accelerate partnerships with pharma, biotech, and academic laboratories.

If CubaseBio can deliver on its promise of affordable, high‑throughput 3‑D transcriptomics, the impact on drug discovery could be profound. Researchers would gain unprecedented insight into cellular heterogeneity within intact tissue architectures, enabling more accurate target identification and validation. Moreover, the technology’s compatibility with existing sequencing infrastructure lowers adoption barriers, potentially making volumetric DNA microscopy a standard assay in pre‑clinical pipelines. As the market for spatial omics is projected to exceed $2 billion by 2028, CubaseBio’s early‑stage commercial push could secure a leading position in a rapidly expanding segment of precision‑medicine tools.